Equities research analysts predict that Heska Corp (NASDAQ:HSKA) will report sales of $30.44 million for the current quarter, according to Zacks Investment Research. Two analysts have provided estimates for Heska’s earnings. The lowest sales estimate is $30.11 million and the highest is $30.78 million. Heska posted sales of $30.96 million during the same quarter last year, which suggests a negative year over year growth rate of 1.7%. The business is scheduled to announce its next earnings results before the market opens on Tuesday, November 5th.
On average, analysts expect that Heska will report full-year sales of $122.39 million for the current year, with estimates ranging from $121.98 million to $122.80 million. For the next year, analysts expect that the company will report sales of $139.97 million, with estimates ranging from $138.63 million to $141.30 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Heska.
Heska (NASDAQ:HSKA) last announced its quarterly earnings data on Tuesday, August 6th. The medical research company reported ($0.03) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.07) by $0.04. Heska had a return on equity of 6.35% and a net margin of 1.93%. The firm had revenue of $28.15 million for the quarter, compared to the consensus estimate of $29.19 million.
A number of equities analysts recently commented on the company. ValuEngine upgraded Heska from a “buy” rating to a “strong-buy” rating in a research report on Thursday, August 1st. Piper Jaffray Companies assumed coverage on Heska in a research report on Wednesday, September 18th. They set a “neutral” rating and a $68.00 price objective on the stock. Canaccord Genuity reduced their price objective on Heska from $95.00 to $75.00 and set a “buy” rating on the stock in a research report on Thursday, September 12th. Zacks Investment Research downgraded Heska from a “buy” rating to a “hold” rating in a research report on Friday. Finally, BidaskClub upgraded Heska from a “sell” rating to a “hold” rating in a research report on Wednesday, September 18th. Seven analysts have rated the stock with a hold rating, one has issued a buy rating and one has issued a strong buy rating to the stock. Heska presently has an average rating of “Hold” and a consensus target price of $78.25.
Large investors have recently bought and sold shares of the business. Financial Gravity Wealth Inc. purchased a new stake in Heska in the second quarter valued at $29,000. Zurcher Kantonalbank Zurich Cantonalbank raised its position in Heska by 175.7% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 670 shares of the medical research company’s stock valued at $47,000 after purchasing an additional 427 shares during the period. Aperio Group LLC purchased a new stake in Heska in the second quarter valued at $79,000. Quantamental Technologies LLC purchased a new stake in Heska in the second quarter valued at $120,000. Finally, Bank of Montreal Can raised its position in Heska by 30.3% in the second quarter. Bank of Montreal Can now owns 2,162 shares of the medical research company’s stock valued at $183,000 after purchasing an additional 503 shares during the period. Institutional investors own 89.08% of the company’s stock.
Heska stock traded down $0.57 during trading on Friday, reaching $75.93. 59,140 shares of the company were exchanged, compared to its average volume of 90,565. Heska has a 52-week low of $62.47 and a 52-week high of $107.00. The company has a market capitalization of $596.44 million, a P/E ratio of 53.47 and a beta of 1.04. The company has a debt-to-equity ratio of 0.04, a current ratio of 3.93 and a quick ratio of 2.05. The stock’s 50 day simple moving average is $70.97 and its two-hundred day simple moving average is $76.07.
Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The company's Core Companion Animal segment offers Element DC and DRI-CHEM 7000 veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element HT5 and HemaTrue veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; Element COAG veterinary analyzers; and IV infusion pumps.
See Also: Roth IRA
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.